Related Information
This brochure will help you understand how the portability features of Novoeight—with stability up to 104°F for up to 3 months—may be appropriate for your patients with active lifestyles.
Novoeight® (antihemophilic factor, recombinant) is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management, and routine prophylaxis to reduce the frequency of bleeding episodes.